Galmed Pharmaceuticals Valuation
Is GPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GPH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GPH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GPH?
Key metric: As GPH is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is GPH's PB Ratio? | |
|---|---|
| PB Ratio | 0.2x |
| Book | US$18.44m |
| Market Cap | US$4.14m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does GPH's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.8x | ||
CNW co.don | 1x | n/a | €6.5m |
T5O bioXXmed | 13.2x | n/a | €1.4m |
MDG1 Medigene | 1.2x | -4.1% | €22.6m |
VSC 4SC | 44x | n/a | €49.1m |
GPH Galmed Pharmaceuticals | 0.2x | n/a | €4.1m |
Price-To-Book vs Peers: GPH is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (19.5x).
Price to Book Ratio vs Industry
How does GPH's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: GPH is good value based on its Price-To-Book Ratio (0.2x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is GPH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate GPH's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$16.25
7D
2.5%
1Y
89.8%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%